How 14B diabetes data points help us make personalization better

It’s been an exciting few weeks for us here at Glooko as we continue to hit many important milestones. First, we have amassed more than 14 billion diabetes data points (14.8 to be precise) allowing us to deliver our annual benchmark, and more impactfully to provide more personalized experiences for our users. We also just released a very exciting version of our mobile app available on both iOS and Android which makes all of our self-management features free to anyone with diabetes!  And finally, we added support for a new and breakthrough implantable CGM, the Senseonics Eversense.

We are in the business of using data to help people with diabetes and their care teams make better decisions. So with 14B+ data points, we can use what we learn to personalize insights, improving the effectiveness of the patterns and trends we present to users. Whether it be a personal decision someone makes about food, exercise, meditation or medications or a decision a clinician makes related to the care plan for an individual patient, data makes these decisions more accurate and more personal.

Instead of a clinician using only standards to drive a care plan, when they use real daily data, beyond labs, that are relevant to the individual, the results can be better outcomes and more effective medication management. While using personal, longitudinal data sounds like an obvious thing to do, up until now, it has been largely void in medical practice, but it can have big impact – here’s how:

Set more impactful personal goals

Most clinicians, nutritionists and CDEs make standard of care recommendations to patients when they come in for a visit. This typically includes watching carb and salt intake, eating more protein and getting at least 20 minutes of exercise each day.  They use patient historical data (typically an A1C result) and anecdotal data they gather directly from the patient to make it a little more personal. While this is an important way to engage with a patient, with more data, recommendations are more impactful and relevant. Details about when an individual experiences glycemic highs and lows, which exercise has the biggest impact on control and which foods drive the most variance for a specific individual can help to provide a much more personal view and improve recommended goals set by clinicians, not -to-mention improve personal decision making in-between visits.

Improve medication dosage and timing

Medication dosage and when an individual should take their medication is probably one of the most impactful things that personal data can drive. In fact, using patient data to drive self-titration of insulin, supported by a mobile application and an Internet-based diabetes management program will both enable and empower PWDs to self-manage their diabetes and achieve glycemic control, while allowing their clinical team to manage them at scale. Patients with greater self-efficacy will not only have improved glycemic control, but also greater adherence to self-care behaviors and medication intake.  

Uncover drivers of personal improvement

For some people, a daily exercise class can make the difference in their glycemic control. For others, it’s that walk around the block after each meal, going carb free or meditating when stress gets high. The impact food, exercise, medications and even meditation can have on each of us differs based on our size, family medical history, and of course our current metabolic rate (did you know metabolic rate changes based on age and even time of year?) With your personalized data, Glooko is able to tell you and your clinician what works for you and what doesn’t. It’s not just the standard “exercise more and eat better”, but rather what specific actions you do that can make an impact on your personal health.

Understand population level trends

For people around the world to garner the personal benefits of precision medicine, it is critical for us to safely and continuously capture and use data to dig deeper into what drives the progression of diabetes in the general population and among sub-populations. Glooko partners with health systems to use de-identified data to conduct studies and better understand both big trends and the nuances of diabetes on certain patient populations. In addition, clinicians have used Glooko to study specific groups in their practices (teenage girls, adults with T2D, remotely monitored adults, pregnant women, etc.) in order to uncover insights that can improve overall diabetes care.

If you want a glimpse of the impact of data, check out our benchmark, or better yet, download Glooko and start tracking your behavior, see your trends and learn how you can improve.


Dave Conn

Dave is Glooko's Chief Commercial Officer and is a veteran in the diabetes industry, with nearly 25 years in leadership roles at companies including J&J and AgaMatrix. He has been focused on Digital Health for the last 8-10 years and is excited to see digital health become more mainstream.